Trifluoperazine

Should be taken with food.

Comatose or greatly depressed states due to CNS depressants; bone marrow suppression, blood dyscrasias, phaeochromocytoma. Hepatic impairment.

Patient with CV disease (e.g. arrhythmia, angina pectoris), hypovolaemia, diabetes, decreased gastrointestinal motility, paralytic ileus, urinary retention, benign prostatic hyperplasia, xerostomia, visual problems (e.g. narrow-angle glaucoma); predisposition to aspiration pneumonia (e.g. Alzheimer's disease), risk factors for blood dyscrasias (e.g. history of drug-induced leucopenia/neutropenia, pre-existing low WBC); myasthenia gravis, Parkinson's disease, cerebrovascular disease, history of seizures, epilepsy, previous brain damage, alcoholism. Patient subjected to dehydration, strenuous exercise, and extreme heat exposure. Discontinue at least 48 hours prior to myelography and do not resume for at least 24 hours postprocedure. Avoid use in the control of nausea and vomiting occurring before myelography or postprocedure with metrizamide. Not approved for the treatment of dementia-related psychosis. Avoid abrupt withdrawal. Debilitated patients. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, dizziness and visual disturbances; if affected, do not drive or operate machinery. Monitoring Parameters Monitor vital signs, mental status, and CBC as necessary; electrolytes and LFTs annually then as clinically indicated; weight, height, BMI, and waist circumference at baseline, every visit for the 1st 6 months, then quarterly with stable dose; fasting plasma glucose level/HbA_1c and lipid panel at baseline and as clinically indicated. Monitor for abnormal involuntary movements or parkinsonian signs, tardive dyskinesia, and visual changes. Perform ocular examination.

Significant: Anticholinergic effects (e.g. constipation, xerostomia, blurred vision, urinary retention), blood dyscrasias (e.g. leucopenia, neutropenia, thrombocytopenia, anaemia, pancytopenia); oesophageal dysmotility or aspiration, CNS depression, falls; extrapyramidal symptoms (e.g. pseudoparkinsonism, acute dystonic reactions, akathisia, tardive dyskinesia); liver damage, cholestatic jaundice; hyperprolactinaemia, pigmentary retinopathy, lenticular and corneal deposits (prolonged use), orthostatic hypotension, venous thromboembolism, impaired core body temperature regulation, lowered seizure threshold; may mask toxicity of other conditions (e.g. brain tumour, Reye's syndrome, intestinal obstruction) due to its antiemetic effects. Eye disorders: Corneal changes, lens disease. Gastrointestinal disorders: Nausea, vomiting, constipation, stomach pain. General disorders and administration site conditions: Fatigue. Investigations: Increased weight. Metabolism and nutrition disorders: Anorexia, hyperglycaemia. Musculoskeletal and connective tissue disorders: Muscle weakness. Nervous system disorders: Drowsiness, dizziness, headache. Psychiatric disorders: Insomnia, agitation. Renal and urinary disorders: Difficulty in micturition, urinary retention. Reproductive system and breast disorders: Change in libido, galactorrhoea, gynaecomastia, amenorrhoea, ejactulatory disorder. Respiratory, thoracic and mediastinal disorders: Nasal congestion. Skin and subcutaneous tissue disorders: Rash, photosensitivity reactions.
Potentially Fatal: Arrhythmias, agranulocytosis, neuroleptic malignant syndrome.

May potentiate the effects of antihypertensives, anticholinergics, and antidepressants. May enhance the CNS depressant effects with sedatives, hypnotics, anaesthetics, and strong analgesics. May antagonise the activity of epinephrine, clonidine, guanethidine and levodopa. May diminish the therapeutic efficacy of oral anticoagulants. Increased risk of severe extrapyramidal effects and neurotoxicity with lithium. May decrease absorption with antacids.

Antiemetics / Antipsychotics / Anxiolytics

N05AB06 - trifluoperazine ; Belongs to the class of phenothiazine antipsychotics with piperazine structure.